R&D (Research and development)


Drug Development Pipeline (As of May 2023)


Approved Drug

ETUARY®(艾思瑞® in Chinese)
Indication : Idiopathic Pulmonary Fibrosis (Obtained Manufacturing and Distribution Permission in December, 2013)
(Start selling as the Class 1.1 in February, 2014)

Clinical Development Stage

ETUARY®(艾思瑞® in Chinese)
Radiation-induced Pneumonitis:Launched pre-Phase III clinical trial pilot study
Indication: Liver Fibrosis- Phase II clinical trials, June.2015
Indication: Chronic Kidney Failure (CKD)- Preclinical stage
Indication: Acute promyelocytic leukemia(APL)- Preparation for Import Permit application

IND(Investigational new drug application) Stage

ETUARY®(艾思瑞® in Chinese)
Indication: Diabetic Nephropathy(DN)-January.2014
Indication: Connective Tissue Disease Associated Interstitial Lung Disease (CTD-ILD) -October.2014
Indication: Acute liver failure/ Acute-on-chronic liver failure (ACLF) -July.2011